Bristol Myers Squibb (BMY) is set for an important FDA action date on March 6 regarding its supplemental New Drug Application for Sotyktu, intended to treat adults with active psoriatic arthritis. Despite a projected revenue decline of 6.3% and an anticipated 18.89% drop in EPS, the company's stock has seen a robust 12.56% increase in the past month, closing at $62.37, above the industry price target average. This growth comes amid strategic measures to offset $30 billion in expected patent losses by 2030, as investor confidence is bolstered by recent clinical advances.
“Bristol Myers Squibb’s (BMY) · has an FDA action date for · supplemental New Drug Application for Sotyktu · to treat adults with active psoriatic arthritis”
“Bristol-Myers Squibb Co. · has volume · 20,673,944”
“Bristol Myers Squibb · will have an FDA action date · for Sotyktu · to treat adults with active psoriatic arthritis”
“The FDA · action date is for · Bristol Myers Squibb’s supplemental New Drug Application · to treat adults with active psoriatic arthritis”
“Bristol Myers Squibb · is rated · Sector Perform · true”
“Bristol Myers Squibb · has a price target of · $60 · true”
“Bristol Myers Squibb · has an FDA action date for · sSupplemental New Drug Application for Sotyktu · March 6”
“Bristol Myers Squibb (BMY) · ended the recent trading session at · $62.37 · +2.08%”
“Bristol Myers Squibb (BMY) · gained · 12.56% · in the past month”
“Bristol Myers Squibb (BMY) · is anticipated to report an EPS of · $1.46 · an 18.89% fall compared to the same quarter of the previous year”
“Bristol Myers Squibb · currently has a Zacks Rank of · #3 · (Hold)”
“Bristol Myers Squibb · has a Forward P/E ratio of · 9.8 · which marks a discount compared to its industry average Forward P/E of 20.16”
.svg&width=160)
